Big Pharma Lays Off Fewer Sales Reps In 2013
Pharmaceutical sales forces have taken a huge hit over the last few years as the industry reorganizes and shifts its priorities. Yet, experts believe that pharma companies will begin hiring reps back in coming years as they believe more new drugs will be approved.
You may also be interested in...
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.
The upcoming Therapeutic Area Partnership conference will showcase companies in niche areas that are prime targets for partnerships or acquisitions.